Rating Change
JP Morgan reiterated its Neutral rating on Upstream Bio, Inc. (NASDAQ:UPB) on August 14, 2026.
JP Morgan reiterated its Neutral rating on Upstream Bio, Inc. (NASDAQ:UPB) on August 14, 2026.

At publication ·
Upstream Bio, Inc. (NASDAQ:UPB) · reiterate
At a glance
JP Morgan reiterated its Neutral rating on Upstream Bio, Inc. (NASDAQ:UPB) on August 14, 2026.
Upstream Bio, Inc. operates in the Healthcare sector. The stock currently trades at $7.07 with a market capitalization of $1.5B.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Upstream Bio, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | JP Morgan | Neutral | N/A |
| Aug 12, 2026 | Truist Securities | Buy | N/A |
| Jun 12, 2026 | JP Morgan | Neutral | N/A |
| Jun 03, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 14, 2026 | Mizuho | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View UPB Stock Page
A rating of Neutral from JP Morgan reflects the analyst's outlook on Upstream Bio, Inc. (NASDAQ:UPB). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the UPB forecast page.
Current market data
NASDAQ · UPB
Keep reading